niacin has been researched along with Adolescent Obesity in 1 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galescu, OA | 1 |
| Crocker, MK | 1 |
| Altschul, AM | 1 |
| Marwitz, SE | 1 |
| Brady, SM | 1 |
| Yanovski, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children[NCT01237041] | Phase 1/Phase 2 | 37 participants (Actual) | Interventional | 2011-07-01 | Terminated (stopped due to Study Medication unavailable) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Effect of niacin vs placebo on Free Fatty Acids (FFA) Area Under the Curve in response to Niacin and Placebo over 4 hours. For FFA, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes (NCT01237041)
Timeframe: 4 hours
| Intervention | Min*UEq/L (Mean) |
|---|---|
| Niacin FFA AUC | |
| Dose-Establishing Study 1 Niacin 250mg | 164056 |
| Dose-Establishing Study 1 Niacin 500mg | 94346 |
| Dose-Establishing Study 2 Niacin 500mg | 48870 |
Effect of niacin vs placebo on Free Fatty Acids (FFA) Area Under the Curve in response to Niacin and Placebo over 4 hours. For FFA, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes (NCT01237041)
Timeframe: 4 hours
| Intervention | Min*UEq/L (Mean) | |
|---|---|---|
| Niacin FFA AUC | Placebo FFA AUC | |
| All Randomized Subjects | 37567 | 106047 |
Growth hormone Area Under the Curve in response to niacin versus placebo over 4 hours. For growth hormone, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes. (NCT01237041)
Timeframe: 4 hours
| Intervention | min*ng/mL (Mean) |
|---|---|
| Niacin | |
| Dose-Establishing Study 1 Niacin 250mg | 32.0 |
| Dose-Establishing Study 1 Niacin 500mg | 84.0 |
| Dose-Establishing Study 2 Niacin 500mg | 394.6 |
Growth hormone Area Under the Curve in response to niacin versus placebo over 4 hours. For growth hormone, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes. (NCT01237041)
Timeframe: 4 hours
| Intervention | min*ng/mL (Mean) | |
|---|---|---|
| Niacin | Placebo | |
| All Randomized Subjects | 589.6 | 638.5 |
Growth hormone-releasing hormone (GHRH) Area Under the Curve in response to Niacin and Placebo over 4 hours. For GHRH, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours
| Intervention | min*pg/mL (Mean) |
|---|---|
| Niacin GHRH | |
| Dose-Establishing Study 1 Niacin 250mg | 2415 |
| Dose-Establishing Study 1 Niacin 500mg | 2548 |
| Dose-Establishing Study 2 Niacin 500mg | 5382 |
Growth hormone-releasing hormone (GHRH) Area Under the Curve in response to Niacin and Placebo over 4 hours. For GHRH, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours
| Intervention | min*pg/mL (Mean) | |
|---|---|---|
| Niacin GHRH | Placbo GHRH | |
| All Randomized Subjects | 2535 | 2283 |
Effect of niacin vs placebo on Somatostatin (SST) Area Under the Curve in response to Niacin and Placebo over 4 hours. For somatostatin, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours
| Intervention | min*pg/mL (Mean) |
|---|---|
| Niacin Somatostatin | |
| Dose-Establishing Study 1 Niacin 500mg | 849.8 |
| Dose-Establishing Study 2 Niacin 500mg | 1578 |
Effect of niacin vs placebo on Somatostatin (SST) Area Under the Curve in response to Niacin and Placebo over 4 hours. For somatostatin, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours
| Intervention | min*pg/mL (Mean) | |
|---|---|---|
| Niacin Somatostatin | Placebo Somatostatin | |
| All Randomized Subjects | 1329 | 1248 |
1 trial available for niacin and Adolescent Obesity
| Article | Year |
|---|---|
A pilot study of the effects of niacin administration on free fatty acid and growth hormone concentrations in children with obesity.
Topics: Blood Glucose; Body Mass Index; Child; Fatty Acids, Nonesterified; Female; Growth Hormone; Humans; I | 2018 |